• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [18422 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brivaracetam - addendum to commission A16-08]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brivaracetam - benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brodalumab (plaque psoriasis) – benefit assessment according to §35a Social Code Book V]
2008     Committee for New Health Technology Assessment (CNHTA) [Bronchial provocation test]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Bronchial thermoplasty in severe asthma]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Budget impact analysis of a telemedicine procedure in quality assurance programs for spirometry in patients with COPD]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Budget impact analysis of increasing kidney transplantation in Québec]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Building planning and infection control: hand hygiene dispensers and individual bathrooms in residential and long-term care centres]
2009     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bupropion, mirtazapine, and reboxetine in the treatment of depression]
2010     National Evidence-based Healthcare Collaborating Agency (NECA) [Burden of irritable bowel syndrome in Korea]
2013     Haute Autorite de sante (HAS) [Bypass prostheses]
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Bypass surgery performed with or without the use of heart-lung machine]
2011     Committee for New Health Technology Assessment (CNHTA) [C-11-acetate positron emission tomography, positron emission tomography/computed tomography]
2020     Andalusian Health Technology Assessment Area (AETSA) [C-Reactive Protein point-of-care testing (CRP-POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections]
2012     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabazitaxel - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Cabazitaxel, abiraterone and enzalutamide in metastatic castration-resistant prostate cancer not responding to docetaxel]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib - assessment according to section 35a (paragraph 1, sentence 10) Social Code Book V (dossier assessment)]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - addendum to order A16-69]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Caesarean section on maternal request: a health technology assessment]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Calreticulin gene mutation testing in myeloproliferative neoplasms]
2011     Committee for New Health Technology Assessment (CNHTA) [Camera manipulating robot assisted endoscopic surgery]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Canagliflozin, empagliflozin and dapagliflozin (SGLT-2) for patients with type 2 diabetes]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Canagliflozin, empagliflozin and dapagliflozin in type 2 diabetes patients]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Canagliflozin: benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Canagliflozin/metformin. Benefit assessment according to section 35a Social Code Book V (dossier assessment)]
2013     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Canaloplasty for open angle glaucoma]
2001     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Cancer of the colon and rectum - diagnosis and screening]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Cannabinoids in patients with autism spectrum disorders]
2005     Andalusian Health Technology Assessment Area (AETSA) [Cannabis therapeutic utility]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Caplacizumab (acquired thrombotic thrombocytopenic purpura) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2007     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Capsule endoscopies of the small intestine - a health technology assessment]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Cardiac contractility modulation for heart failure- 2nd Update 2010]
2010     Haute Autorite de sante (HAS) [Cardiac markers in coronary disease and heart failure in outpatient medicine]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Cardiac rehabilitation - a health technology assessment: evidence from the literature and the DANREHAB trial]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Cardiac resynchronization therapy: multi-site pacemaker use]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Cardiac resynchronization therapy. Economic evaluation]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Cardiac surgery registry. An international review]
2009     Committee for New Health Technology Assessment (CNHTA) [Cardio detect(h-FABP)]
2013     Andalusian Health Technology Assessment Area (AETSA) [CardioWest™ TAH-t. Total artificial heart]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib - assessment according to §35a (para. 1, sentence 10) Social Code Book V]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma; combination with dexamethasone alone) – assessment according to § 35a (para.1, sentence 10) Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma) – benefit assessment according to §35a Social Code Book V]
2008     Committee for New Health Technology Assessment (CNHTA) [Caries diagnosis with laser fluorescence(Diagnodent)]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Carotid echo doppler for plaque area measurement in cardiovascular risk stratification]
2011     Basque Office for Health Technology Assessment (OSTEBA) [Case and control study: efficiency of psychoeducational treatment of the overload experienced by family members of bipolar patients]
2012     The Swedish Council on Health Technology Assessment (SBU) [Case finding, diagnosis and follow up of patients with affective disorders]
2012     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Catalan arthroplasty register. 2nd report (data 2005-2010)]
2010     The Swedish Council on Health Technology Assessment (SBU) [Catheter ablation for atrial fibrillation (update)]
2005     The Swedish Council on Health Technology Assessment (SBU) [Catheter ablation of atrial fibrillation - early assessment briefs (Alert)]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Catheter-directed mechanical thrombolysis in thromboembolic disease]
2008     Committee for New Health Technology Assessment (CNHTA) [CBFB/MYH11 rearrangement, Quantification [Real-time RT-PCR]]
2009     Committee for New Health Technology Assessment (CNHTA) [CD4 lymphocyte activity (bioluminescent assay)]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Ceftazidime/avibactam in severe infections]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Central auditory processing disorder diagnosis]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Cerebrospinal fluid neurotransmitter screening in encephalopathies]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib - benefit assessment according to §35a Social Code Book V (dossier assessment)]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib (lung cancer): Addendum to Commission A16-62]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib (lung cancer): benefit assessment according to §35a Social Code Book V; expiry of the decision
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib (non-small cell lung cancer) – benefit assessment according to §35a Social Code Book V]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Ceritinib for the treatment of ALK-positive metastatic non-small cell lung cancer]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Ceritinib in lung cancer]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cerliponase alfa (neuronal ceroid lipofuscinosis) - assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Cerliponase alfa in neuronal ceroid lipofuscinosis type 2]
2010     Haute Autorite de sante (HAS) [Cervical length measurement with transvaginal ultrasonography to predict spontaneous preterm birth]
2011     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cessation of smoking in essential hypertension - Rapid report]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Cetuximah given in combination for patients with colorectal cancer]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Checklist for ethical and legal domains analysis]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Chemoembolization and radioembolization for the treatment of liver metastases]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Choice-based conjoint analysis: pilot project to identify, weight, and prioritize multiple attributes in the indication "hepatitis C"]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cholic acid: assessment according to section 35a (paragraph 1, sentence 10) Social Code Book V (dossier assessment)]
2012     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [ChondroCelect® in patients with knee cartilage injury]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Chromosomal microarrays for the etiologic diagnosis in patients with intellectual disability, developmental delay or autism spectrum]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Chronic fatigue syndrome: state of the evidence and assessment of intervention modalities in Quebec]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Chronic hepatitis C. Combination therapy IFN and ribavirin]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Chronic low back pain: the appropriate use of diagnostic imaging procedures]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Chronic periodontitis - prevention, diagnosis and treatment]
2014     The Swedish Council on Health Technology Assessment (SBU) [Chronic ulcers in the elderly – prevention and treatment]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Cidofovir for the treatment of recurrent respiratory papillomatosis]
2010     The Swedish Council on Health Technology Assessment (SBU) [Cilostazol for treatment of intermittent claudication]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Circulating tumour cells in breast cancer: clinical use of the CellSearch® test]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Classification of disease severity for neuro- and trauma rehabilitation Part 3: Status quo in Austria]
2008     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Clavicular fractures - a systematic review about efficacy and safety of different treatment options]
2020     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical Efectiveness of Newborn Screening for Inborn Errors of Metabolism by MS/ MS. Update and pilot study assessment: Maple Syrup Urine Disease; Isovaleric Acidaemia; Homocystinuria]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Clinical effectiveness and cost-effectiveness of central venous catheters treated with minocycline and rifampicin in preventing bloodstream infections in intensive care patients]
2014     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Clinical effectiveness and cost-effectiveness of fissure sealants in children and adolescents with a high caries risk]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Clinical effectiveness and cost-effectiveness of non-invasive telemonitoring on patients with heart failure]
2013     National Evidence-based Healthcare Collaborating Agency (NECA) [Clinical effectiveness and safety of robotic surgery]
2005     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Clinical effectiveness of carvedilol in comparison to -blockers, systematic review of the clinical and economic literature]
2005     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Clinical effectiveness of indapamide; systematic review of the clinical and economic literature]
2007     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry. Systematic Review]
2013     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry: Maple Syrup Urine Disease, Homocystinuria, Glutaric Aciduria Type I, Isovaleric Acidaemia, Long-chain 3-Hydroxyacyl CoA Dehydrogenase Deficiency]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part III: carnitine uptake deficiency (CUD); short-chain acyl-CoA dehydrogenase deficiency (SCADD); very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part IV: Beta-kethiolase deficiency (BKT); 3-Hydroxy-3-methyl glutaric aciduria (HMG)]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part IV: β-ketothiolase deficiency (BKT); 3-hydroxy-3-methyl glutaric aciduria (HMG)]
2014     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism. Part II: Methylmalonic acidemia, Propionic acidemia, Tyrosinemia type I]
2018     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for severe combined immunodeficiency]